Income Statement Thermo Fisher Scientific, Inc.
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 578.90 USD | +0.89% |
|
+0.64% | +11.28% |
| Dec. 11 | Citigroup Upgrades Thermo Fisher Scientific to Buy From Neutral, Adjusts PT to $660 From $580 | MT |
| Dec. 08 | Why the Fed's Next Move Matters More Than Markets Admit |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 32.22B | 39.21B | 44.92B | 42.86B | 42.88B | |||||
Total Revenues | 32.22B | 39.21B | 44.92B | 42.86B | 42.88B | |||||
Cost of Goods Sold, Total | 16.21B | 19.57B | 25.92B | 25.74B | 25.13B | |||||
Gross Profit | 16.01B | 19.64B | 19B | 17.11B | 17.75B | |||||
Selling General & Admin Expenses, Total | 6.96B | 8B | 8.94B | 8.38B | 8.6B | |||||
R&D Expenses | 1.18B | 1.41B | 1.47B | 1.34B | 1.39B | |||||
Other Operating Expenses | - | 3M | - | 1M | 30M | |||||
Other Operating Expenses, Total | 8.14B | 9.41B | 10.41B | 9.72B | 10.02B | |||||
Operating Income | 7.87B | 10.23B | 8.59B | 7.39B | 7.73B | |||||
Interest Expense, Total | -553M | -536M | -726M | -1.38B | -1.39B | |||||
Interest And Investment Income | 65M | 43M | 272M | 879M | 1.08B | |||||
Net Interest Expenses | -488M | -493M | -454M | -496M | -312M | |||||
Income (Loss) On Equity Invest. | - | -4M | -172M | -59M | -42M | |||||
Currency Exchange Gains (Loss) | -81M | 162M | 102M | -29M | -16M | |||||
Other Non Operating Income (Expenses) | 81M | -161M | -35M | 5M | 5M | |||||
EBT, Excl. Unusual Items | 7.38B | 9.73B | 8.03B | 6.82B | 7.37B | |||||
Restructuring Charges | -18M | -37M | -95M | -233M | -104M | |||||
Merger & Related Restructuring Charges | -81M | -35M | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 10M | 66M | -161M | -46M | 21M | |||||
Gain (Loss) On Sale Of Assets | - | - | 14M | - | - | |||||
Asset Writedown | -34M | -122M | -60M | -219M | -252M | |||||
Legal Settlements | - | - | - | -19M | - | |||||
Other Unusual Items | -37M | -767M | -63M | -59M | -39M | |||||
EBT, Incl. Unusual Items | 7.22B | 8.84B | 7.66B | 6.24B | 7B | |||||
Income Tax Expense | 850M | 1.11B | 703M | 284M | 657M | |||||
Earnings From Continuing Operations | 6.38B | 7.73B | 6.96B | 5.96B | 6.34B | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 6.38B | 7.73B | 6.96B | 5.96B | 6.34B | |||||
Minority Interest | - | -3M | -10M | 40M | -3M | |||||
Net Income - (IS) | 6.38B | 7.72B | 6.95B | 6B | 6.34B | |||||
Net Income to Common Incl Extra Items | 6.38B | 7.72B | 6.95B | 6B | 6.34B | |||||
Net Income to Common Excl. Extra Items | 6.38B | 7.72B | 6.95B | 6B | 6.34B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 16.1 | 19.61 | 17.73 | 15.53 | 16.58 | |||||
Basic EPS - Continuing Operations | 16.1 | 19.61 | 17.73 | 15.53 | 16.58 | |||||
Basic Weighted Average Shares Outstanding | 396M | 394M | 392M | 386M | 382M | |||||
Net EPS - Diluted | 15.96 | 19.46 | 17.63 | 15.45 | 16.53 | |||||
Diluted EPS - Continuing Operations | 15.96 | 19.46 | 17.63 | 15.45 | 16.53 | |||||
Diluted Weighted Average Shares Outstanding | 399M | 397M | 394M | 388M | 383M | |||||
Normalized Basic EPS | 11.66 | 15.43 | 12.77 | 11.14 | 12.05 | |||||
Normalized Diluted EPS | 11.57 | 15.31 | 12.71 | 11.08 | 12.02 | |||||
Dividend Per Share | 0.88 | 1.04 | 1.2 | 1.4 | 1.56 | |||||
Payout Ratio | 5.29 | 5.11 | 6.55 | 8.72 | 9.2 | |||||
American Depositary Receipts Ratio (ADR) | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |||||
Supplemental Items | ||||||||||
EBITDA | 10.2B | 12.82B | 11.97B | 10.8B | 10.84B | |||||
EBITA | 9.54B | 11.99B | 10.98B | 9.73B | 9.69B | |||||
EBIT | 7.87B | 10.23B | 8.59B | 7.39B | 7.73B | |||||
EBITDAR | 10.47B | 13.14B | 12.43B | 11.27B | 11.31B | |||||
Total Revenues (As Reported) | 32.22B | 39.21B | 44.92B | 42.86B | 42.88B | |||||
Effective Tax Rate - (Ratio) | 11.76 | 12.55 | 9.17 | 4.55 | 9.39 | |||||
Current Domestic Taxes | 696M | 606M | 1.07B | 378M | 691M | |||||
Current Foreign Taxes | 423M | 1.15B | 633M | 1.21B | 1.18B | |||||
Total Current Taxes | 1.12B | 1.75B | 1.7B | 1.58B | 1.87B | |||||
Deferred Domestic Taxes | -251M | -246M | -683M | -653M | -1.14B | |||||
Deferred Foreign Taxes | -18M | -399M | -314M | -647M | -72M | |||||
Total Deferred Taxes | -269M | -645M | -997M | -1.3B | -1.21B | |||||
Normalized Net Income | 4.62B | 6.08B | 5.01B | 4.3B | 4.6B | |||||
Non-Cash Pension Expense | 10M | -6M | -16M | -5M | 0 | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 1.18B | 1.41B | 1.47B | 1.34B | 1.39B | |||||
Net Rental Expense, Total | 273M | 320M | 460M | 470M | 468M | |||||
Imputed Operating Lease Interest Expense | 58.78M | 46.57M | 73.7M | 142M | 150M | |||||
Imputed Operating Lease Depreciation | 214M | 273M | 386M | 328M | 318M | |||||
Stock-Based Comp., Other (Total) | 196M | 230M | 307M | 278M | 301M | |||||
Total Stock-Based Compensation | 196M | 230M | 307M | 278M | 301M |
- Stock Market
- Equities
- TMO Stock
- Financials Thermo Fisher Scientific, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















